Cipher Pharmaceuticals Inc
PHE
Company Profile
Business description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
Contact
5750 Explorer Drive
Suite 404
MississaugaONL4W 0A9
CANT: +1 905 602-5840
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.40 | 53.60 | -0.58% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,195.92 | 37.56 | 0.14% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 52,446.08 | 34.74 | 0.07% |
| NZX 50 Index | 13,600.94 | 44.64 | 0.33% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,835.00 | 47.70 | -0.54% |
| SSE Composite Index | 3,974.08 | 2.45 | -0.06% |